Pfizer to start study evaluating omicron-based COVID vaccine
2 years ago
53
On Tuesday, Pfizer announced it is starting a clinical study to evaluate the safety, tolerability, and immunogenicity of an omicron-based vaccine in healthy adults who are 18 through 55. Local health experts are weighing in on what’s behind the study and what it means for you.
Loading comments...
-
2:04
WFTS
7 months agoOngoing storm repairs in St. Petersburg neighborhood
172 -
0:49
Reuters
2 years agoPfizer CEO sees annual COVID vaccine v. boosters
79424 -
0:22
Newsy
2 years agoPfizer Opens Study Of Omicron-Specific COVID-19 Vaccine
47313 -
1:04
AfricanNewsAgency
2 years ago $1.58 earnedCOVID vaccine: AstraZeneca is more effective than Pfizer, study reveals (1)
5.34K8 -
1:04
AfricanNewsAgency
2 years ago $0.34 earnedCOVID vaccine: AstraZeneca is more effective than Pfizer, study reveals (1)
1.77K1 -
3:15
WXYZ
2 years agoFDA fully approves Pfizer COVID vaccine
1.53K20 -
0:18
WFTS
2 years agoPfizer says it's starting clinical studies of an omicron-based COVID-19 vaccine
252 -
1:29
Reuters
2 years agoPfizer vaccine less effective after 6 months: study
10.1K82 -
1:22:20
Real Coffee With Scott Adams
19 hours agoEpisode 2465 CWSA 05/05/24
124K77 -
38:35
Standpoint with Gabe Groisman
3 days agoEp. 22. Knesset Speaker on The Challenging Times in Israel. Amir Ohana
131K94
